Royalty Pharma (RPRX) EBITDA Margin Growth (3y) (2022 - 2026)
Royalty Pharma (RPRX) EBITDA Margin Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9,942.00 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 530.00 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1,211.00 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -623.00 |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Royalty Pharma | 25.78 Bn | 28.22 Bn | - | 1,926.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,926.00 |
| Dec 31, 2025 | 14,775.00 |
| Sep 30, 2025 | 3,659.00 |
| Jun 30, 2025 | -3,423.00 |
| Mar 31, 2025 | 5,491.00 |
| Dec 31, 2024 | 3,425.00 |
| Sep 30, 2024 | 7,844.00 |
| Jun 30, 2024 | -8,405.00 |
| Mar 31, 2024 | -5,300.00 |
| Dec 31, 2023 | 4,793.00 |
| Sep 30, 2023 | -6,659.00 |
| Jun 30, 2023 | -3,388.00 |
| Mar 31, 2023 | -213.00 |
| Dec 31, 2022 | -37,645.00 |
| Sep 30, 2022 | -8,118.00 |
| Jun 30, 2022 | -116.00 |